Stonebridge Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Stonebridge Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$247K	Buy	+320	New	+$245K	0.11%	73
2025 Q2	$255K	Hold	485	–	–	0.1%	79
2025 Q1	$308K	Sell	485 -250	-34%	-$172K	0.13%	69
2024 Q4	$524K	Hold	735	–	–	0.21%	60
2024 Q3	$773K	Hold	735	–	–	0.31%	48
2024 Q2	$773K	Hold	735	–	–	0.33%	48
2024 Q1	$707K	Hold	735	–	–	0.32%	49
2023 Q4	$646K	Hold	735	–	–	0.32%	49
2023 Q3	$605K	Sell	735 -10	-1%	-$7.86K	0.33%	48
2023 Q2	$535K	Hold	745	–	–	0.25%	58
2023 Q1	$612K	Hold	745	–	–	0.29%	55
2022 Q4	$538K	Sell	745 -175	-19%	-$129K	0.26%	57
2022 Q3	$634K	Hold	920	–	–	0.33%	49
2022 Q2	$544K	Hold	920	–	–	0.25%	60
2022 Q1	$643K	Hold	920	–	–	0.23%	60
2021 Q4	$581K	Hold	920	–	–	0.2%	63
2021 Q3	$556K	Hold	920	–	–	0.2%	63
2021 Q2	$514K	Hold	920	–	–	0.19%	67
2021 Q1	$435K	Hold	920	–	–	0.17%	69
2020 Q4	$445K	Hold	920	–	–	0.18%	67
2020 Q3	$515K	Hold	920	–	–	0.24%	59
2020 Q2	$560K	Sell	920 -50	-5%	-$28.4K	0.29%	52
2020 Q1	$474K	Sell	970 -50	-5%	-$20.6K	0.27%	60
2019 Q4	$383K	Sell	1,020 -75	-7%	-$25.2K	0.17%	79
2019 Q3	$304K	Sell	1,095 -324	-23%	-$95.9K	0.14%	85
2019 Q2	$445K	Sell	1,419 -740	-34%	-$246K	0.18%	80
2019 Q1	$887K	Sell	2,159 -60	-3%	-$24.7K	0.32%	60
2018 Q4	$829K	Sell	2,219 -25	-1%	-$9.15K	0.33%	63
2018 Q3	$907K	Sell	2,244 -255	-10%	-$97K	0.31%	63
2018 Q2	$902K	Buy	2,499 +166	+7%	+$51.9K	0.32%	62
2018 Q1	$750K	Buy	2,333 +605	+35%	+$210K	0.27%	67
2017 Q4	$634K	Buy	+1,728	New	+$700K	0.23%	71

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Stonebridge Capital Management's REGN Position: Q1 2026 in Review

Stonebridge Capital Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 320 shares worth $247K. The stake represents 0.11% of the portfolio and ranks #73 among its holdings. This is a return to the name: Stonebridge Capital Management previously reported a position in REGN as recently as Q2 2025.

Stonebridge Capital Management first reported a position in REGN in Q4 2017 and has held it in 32 quarters since. The position peaked at $907K in Q3 2018. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Stonebridge Capital Management held 320 shares of Regeneron Pharmaceuticals worth $247K as of Q1 2026.
Regeneron Pharmaceuticals was a new Stonebridge Capital Management position in Q1 2026.
Regeneron Pharmaceuticals made up 0.11% of Stonebridge Capital Management's portfolio in Q1 2026, its #73 holding.
Stonebridge Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 32 quarters since.
Stonebridge Capital Management's Regeneron Pharmaceuticals position peaked at $907K in Q3 2018.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Stonebridge Capital Management's 13F filing for Q1 2026, filed 14 Apr 2026.